

TRANSMITTAL

COPY OF PAPERS ORIGINALLY FILED

December 6, 2001

type a plus spaning the dis box TM + Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/017,327 **Application Number**

Filing Date

First Named Inventor Charles A. NICOLETTE Group Art Unit 1645 AUG 2 (to be used for all correspondence after initial filing) Examiner Name Not Yet Assigned Total Number Of Pages In This Submission 7 Attorney Docket No. GZ 2101.20 ENCLOSURES (check all that apply) After Allowance Communication (for an Application)	R 1600/
(to be used for all correspondence after initial filing) Examiner Name Not Yet Assigned Total Number Of Pages In This Submission 7 Attorney Docket No. GZ 2101.20 ENCLOSURES (check all that apply) After Allowance Communication	R 1600/
Total Number Of Pages In This Submission 7 Attorney Docket No. GZ 2101.20 ENCLOSURES (check all that apply) After Allowance Communication	\preceq
Total Number Of Pages In This Submission 7 Attorney Docket No. GZ 2101.20 ENCLOSURES (check all that apply) After Allowance Communication	\preceq
Assignment Papers After Allowance Communication	
Fee Transmittal Form	
• • • • • • • • • • • • • • • • • • • •	1 to
Fee Attached - Drawing(s) Appeal Communication to Boar Appeals and Interferences	d of
Amendment / Reply Licensing-related Papers Appeal Communication to Grou (Appeal Notice, Brief, Reply Brief)	p
After Final Petition Proprietary Information	
Affidavits/declarations Petition to Convert to a Status Letter Provisional Application	
Extension of Time Request Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Express Abandonment Request Request for Refund Supplemental Information Disclosure Statement w/ PTO 1449A & PTO 1449B Certified Copy of Priority Document(s) Response to Missing Parts/ Cher Enclosure(s) (please identification) Power of Attorney, Revocation Change of Correspondence Address Other Enclosure(s) (please identification) Postcard receipt Cthange of Correspondence Address Other Enclosure(s) (please identification) Postcard receipt Cthange of Correspondence Address Other Enclosure(s) (please identification) Postcard receipt Request for Refund Request for Refund Republication Republic	у
Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	
SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Antoinette F. Konski	
Firm Antoinette F. Konski Binghary McCutchen LLP (formerly McCutchen Doyle Brown & Enersen LLP) Or Three Enbarcadero Center, Suite 1800 Individual Name San Francisco, CA 94111-4067	
Signature Signature	
Date (Mg. 13, 2002	
CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postel Service with sufficient postage as first class an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this date listed below: Dated:	mail in

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PATENT Docket No. GZ 2101.20 GZ Ref. 5028 USP1

CERTIFICATE OF MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C./2011 on this date listed below.

RECEIVED AUG 2 1 2002 TECH CENTER 1600/29 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Charles A. NICOLETTE

Serial No.: 10/017,327

Filing Date: December 6, 2001

For: COMPOUNDS FOR THERAPY AND

DIAGNOSIS AND METHODS FOR

USING SAME

Examiner: Not Yet Assigned

Group Art Unit: 1645

COPY OF PAPERS ORIGINALLY FILED

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached forms PTO-1449a and PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
Within three months after the filing date of the application or within three
months after the date of entry of the national stage of a PCT application as set
forth in 37 C F R & 1 401

	Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
This Informa	tion Disclosure Statement is filed:
	After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No.[] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.
This Informa	tion Disclosure Statement is filed:
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.
The undersig	ned certifies that:
	Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
II. Copies o	f the Cited Items:
	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
	Copies of only the following items listed on the attached Form PTO-1449 are enclosed:
	Copies of the items listed in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. 09/870,216 filed May 30, 2001 and relied upon in this

2

Serial No.: 10/017,327 Docket No.: GZ 2101.20 GZ Ref.: 5028 USP1

		application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).
		Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.
ш.	Concise	Explanation of Relevance:
	\boxtimes	A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
		A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).
IV.	Related	Applications:
		Applicants bring to the Office's attention the following related, co-pending application(s):
v.	Conclus	sion:
Cita	tion of th	e above documents shall not be construed as:
	. 1.	an admission that the documents are necessarily prior art with respect to the instant invention;

- a representation that a search has been made, other than as described above; or 2.
- an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b). 3.

3

Serial No.: 10/017,327 Docket No.: GZ 2101.20 GZ Ref.: 5028 USP1

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks. The Commissioner is hereby authorized to charge Deposit Account No. 50-1189, billing reference number: 19442-7247 for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

Dated:

Bv:

Antoin

ntoinette F. Konski

Registration No. 34,202

Bingham McCutchen LLP (formerly McCutchen Doyle Brown & Enersen LLP)

Three Embarcadero Center, Suite 1800 San Francisco, California 94111-4067

Telephone: (650) 849-4950 Facsimile: (650) 849-4800

PTO/SB/08A (10-01) hrough 10/31/2002. OMB 0651-0031

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ሃአ	
186	- Cu
WA.	
~/.	TRACE
19	THAU THE TANK THE
	Sesulute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Compl	ete if Known
Application Number	10/017,327
Filing Date	December 6, 2001
First Named Inventor	Charles A NICOLETTE
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2101.20

		U.S.	PATENT DO	CUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No.1	Number – Kind Code ² (if known)	MM-DD-YY	Application of Cited Document	Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			DECEIVED
		US-			RECEIVED
		US-			
		US-			AUG 2 1 2002
		US-			
		US-	-		TECH CENTER 1600/290
		US-			LECH OF MEN 1997
		US-			
		US-			

		FOREIGN PAT	TENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	1	WO 97/34613	09-25-97	University of Virginia		
	2	WO 00/20457 A	04-13-00	Genzyme Corp.		
	3	WO 01/92294 A	12-06-01	Genzyme Corp.		
	4	WO 01/92306 A	12-06-01	Genzyme Corp.		
				•		
					<u></u>	

Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

COPY OF PAPERS ORIGINALLY FILED

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for Enrough 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

7	-
_	

TRADEAN		Complete if Known			
ubstitute for form 1449	в-РТО			Application Number	10/017,327
INFOR	ΜΑΤΙΩΝ Γ	nisci o	SURE	Filing Date	December 6, 2001
INFORMATION DISCLOSURE			- "	First Named Inventor	Charles A. NICOLETTE
STATEMENT BY APPLICANT		CANI	Art Unit	1645	
(use	as many sheets	as necessa	ary)	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	GZ 2101.20

Initials* No. serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published ASANO, K. et al. "Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits" J. Biol. Chem. (October 24, 1997) 272(43):27042-27052 NUPPONEN, N.N. et al. "Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer" Am. J. Path. (June, 1999) 154(6):1777-1783 RAMAKRISHNA, V. et al. "Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells" Int1 J. Cancer (September 26, 1997) 73(1):143-150 DENTON, G. et al. "Induction of antibody responses to breast cancinoma associated mucins using synthetic peptide constructs as immunogens" Cancer Lets. (July 16, 1993) 70(3):143-150 RECEIVED AUG 2 1 2000 TECH CENTER 16	xaminer	Cite	OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T ²
Chem. (October 24, 1997) 272(43):27042-27052 NUPPONEN, N.N. et al. "Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer" Am. J. Path. (June, 1999) 154(6):1777-1783 RAMAKRISHNA, V. et al. "Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells" Int'l J. Cancer (September 26, 1997) 73(1):143-150 DENTON, G. et al. "Induction of antibody responses to breast cancinoma associated mucins using synthetic peptide constructs as immunogens" Cancer Lets. (July 16, 1993) 70(3):143-150	Initials*	No.1		
initiation factor 3 in breast and prostate cancer" Am. J. Path. (June, 1999) 154(6):1777-1783 RAMAKRISHNA, V. et al. "Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells" Int'l J. Cancer (September 26, 1997) 73(1):143-150 DENTON, G. et al. "Induction of antibody responses to breast cancinoma associated mucins using synthetic peptide constructs as immunogens" Cancer Lets. (July 16, 1993) 70(3):143-150 RECEIVED		1	•	
cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells" Int'l J. Cancer (September 26, 1997) 73(1):143-150 4 DENTON, G. et al. "Induction of antibody responses to breast cancinoma associated mucins using synthetic peptide constructs as immunogens" Cancer Lets. (July 16, 1993) 70(3):143-150 RECEIVE		2		
synthetic peptide constructs as immunogens" Cancer Lets. (July 16, 1993) 70(3):143-150 RECEIVE		3	cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells"	
RECEIVE AUG 2 1 200 TECH CENTER 16		4	·	
RECEIVE AUG 2 1 200 TECH CENTER 16				
AUG 2 1 200 TECH CENTER 16			- OFN/ET)
TECH CENTER 16	·		RECEIVE	
TECH CENTER 16			AUG 2 1 2002	
			TECH CENTER 160	0 25
			120.	
		-		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY OF PAPERS ORIGINALLY FILED

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.